Eurofins Scientific’s organic sales growth was 3.5% in the third quarter, showing a gradual acceleration over the last nine months. Shares were trading about 2% higher intraday on Oct. 21.
There are still sufficient acquisition targets left for Eurofins in its growth markets, allowing it to have continuous high growth while fortifying its competitive positioning through its hub-and-spoke network.
Eurofins has achieved leading positions in key markets primarily through acquisitions. In the future, Eurofins may overpay on acquisitions to meet top-line targets.
|
Metric
|
ERF
|
BVI
|
SGSN
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.17 | 22.55 | 27.94 |
Price/Book Value | 4.06 | 7.82 | 20.16 |
Price/Sales | 2.11 | 2.00 | 2.79 |
Price/Cash Flow | 11.88 | 13.44 | 16.89 |
|
Metric
|
ERF
|
BVI
|
SGSN
|
|---|---|---|---|
Quick Ratio | 0.87 | 1.10 | 0.93 |
Current Ratio | 1.13 | 1.29 | 0.95 |
Interest Coverage | 5.15 | 8.19 | 11.63 |
|
Metric
|
ERF
|
BVI
|
SGSN
|
|---|---|---|---|
Return on Assets (Normalized) | 6.96% | 9.35% | 9.61% |
Return on Equity (Normalized) | 21.47% | 40.08% | 88.73% |
Return on Invested Capital (Normalized) | 9.71% | 15.36% | 13.55% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|x#>&&$lT | LOCK|&^L | $249B | |||
| Danaher Corp
DHR
| LOCK|Q%j!%cL | LOCK|<> | $162B | |||
| Agilent Technologies Inc
A
| LOCK|@hc&dDc% | LOCK|ls | $49B | |||
| IQVIA Holdings Inc
IQV
| LOCK|#ShLcpk | LOCK|#tN<% | $46B | |||
| Waters Corp
WAT
| LOCK|@h@Srf^ | LOCK|C# | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|kn<DD$> | LOCK|CQ^ | $44B | |||
| Illumina Inc
ILMN
| LOCK|!^Pt!s | LOCK|j^?J | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|#<tM>jX% | LOCK|W>&Sl | $33B | |||
| Quest Diagnostics Inc
DGX
| LOCK|ZSz^R#T | LOCK|q>$^r | $27B | |||
| Labcorp Holdings Inc
LH
| LOCK|T>!q&DG | LOCK|wyvYt | $27B |
United States